ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.470,11
-0,70%
S&P 500
5.642,69
0,20%
Dow Jones
40.711,32
1,24%
Euro vs US Dollar
1,08826
-0,16%
Bitcoin
63.241,23
-2,48%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
25/08/202212h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
25/08/202209h02Dow Jones NewsAstraZeneca's Ultomiris, Tagrisso Treatments Approved in JapanNASDAQ:AZNAstraZeneca PLC
25/08/202208h48Dow Jones NewsAstraZeneca Says Lynparza Approved in Japan for Early Breast CancerNASDAQ:AZNAstraZeneca PLC
25/08/202200h34Dow Jones NewsADRs End Mixed; ABB, AstraZeneca Trade ActivelyNASDAQ:AZNAstraZeneca PLC
24/08/202213h00Business WireAstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022NASDAQ:AZNAstraZeneca PLC
23/08/202217h57Dow Jones NewsAstraZeneca Could Exit Vaccine Business, Reuters ReportsNASDAQ:AZNAstraZeneca PLC
16/08/202213h00Business WireLYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancerNASDAQ:AZNAstraZeneca PLC
16/08/202212h18Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
16/08/202208h50Dow Jones NewsAstraZeneca's Lynparza Supplemental New Drug Application Granted Priority Review by FDANASDAQ:AZNAstraZeneca PLC
15/08/202219h29Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
15/08/202208h42Dow Jones NewsEnhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca SaysNASDAQ:AZNAstraZeneca PLC
12/08/202213h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancerNASDAQ:AZNAstraZeneca PLC
12/08/202212h37Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
12/08/202208h53Dow Jones NewsAstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer TreatmentNASDAQ:AZNAstraZeneca PLC
09/08/202212h49Dow Jones NewsAstraZeneca Reports Promising Data From Lung Cancer TrialNASDAQ:AZNAstraZeneca PLC
08/08/202214h45InvestorsHub NewsWireThe Power of Science to Stop a KillerNASDAQ:AZNAstraZeneca PLC
08/08/202213h00Business WireTAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trialNASDAQ:AZNAstraZeneca PLC
08/08/202212h38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
08/08/202212h01GlobeNewswire Inc.HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II TrialNASDAQ:AZNAstraZeneca PLC
08/08/202208h50Dow Jones NewsAstraZeneca's Enhertu Breast Cancer Treatment Approved for Use in USNASDAQ:AZNAstraZeneca PLC
06/08/202202h06Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancerNASDAQ:AZNAstraZeneca PLC
05/08/202220h20Business WireCALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indicationsNASDAQ:AZNAstraZeneca PLC
05/08/202213h59Dow Jones NewsAstraZeneca's Calquence Tablet Formulation Gets FDA ApprovalNASDAQ:AZNAstraZeneca PLC
04/08/202212h05Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
04/08/202208h54Dow Jones NewsAstraZeneca Lynparza Breast Cancer Treatment Approved for Use in EUNASDAQ:AZNAstraZeneca PLC
01/08/202219h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/08/202217h19Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:AZNAstraZeneca PLC
01/08/202212h30Dow Jones NewsInnate Pharma Shares Slide After Failure of Monalizumab in Head, Neck CancerNASDAQ:AZNAstraZeneca PLC
29/07/202209h58Dow Jones NewsAstraZeneca Swung to 2Q Net Loss, but Raises Full-Year Revenue Guidance -- UpdateNASDAQ:AZNAstraZeneca PLC
29/07/202209h19Dow Jones NewsAstraZeneca Appoints Michel Demare as New Chairman-DesignateNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

LSE
SIR
Secure Income Reit
NYSE
CBL
CBL and Associates Prope...
NASDAQ
COUP
Coupa Software
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten